Drugs / CEP-32496
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03784378 | Dec 2018 → Sep 2020 | non-small cell lung carcinoma, ovarian cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01877811 | Jun 2013 → Dec 2018 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03052569 | — | — | Hoffmann-La Roche | No longer available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP-32496 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029988 ↗ |
| Known as | AB-024 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029988 ↗ |
| Known as | AC-013773 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029988 ↗ |
| Known as | Agerafenib | ChEMBL registry synonym — accepted as the source's own label CHEMBL2029988 ↗ |
| Known as | RXDX-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01877811 ↗ |
| Action | Inhibit | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL2029988 ↗ |
| Modality | Small molecule | — CHEMBL2029988 ↗ |
| Route | Oral | “daily oral doses of RXDX-105” NCT01877811 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL2029988 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL2029988 ↗ |
| Target | RET | “RET Inhibitor” NCT01877811 ↗ |